Market Place
Sourcing Support
Viridian Therapeutics Reports Q3 2024 Financial Results & Progress
12 Nov 2024 //
BUSINESSWIRE
Viridian Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
05 Nov 2024 //
BUSINESSWIRE
Viridian Therapeutics Prices Upsized Public Offering Of Shares
11 Sep 2024 //
BUSINESSWIRE
Viridian`s Drug Resolves Eye Disease Symptoms, Challenges Amgen`s Tepezza
11 Sep 2024 //
FIERCE BIOTECH
Viridian Reports Positive Veligrotug Phase 3 THRIVE Results
10 Sep 2024 //
BUSINESSWIRE
Viridian Announces Proposed Public Offering Of Stocks
10 Sep 2024 //
BUSINESSWIRE
Viridian To Share VRDN-001 Phase 3 Results On September 10, 2024
09 Sep 2024 //
BUSINESSWIRE
Viridian Therapeutics Announces Inducement Grants
05 Sep 2024 //
BUSINESSWIRE
Viridian Therapeutics Reports Q2 2024 Results And Recent Progress
08 Aug 2024 //
BUSINESSWIRE
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Rule
07 Aug 2024 //
BUSINESSWIRE
Viridian Completes THRIVE-2 Enrollment For VRDN-001 In Chronic TED
25 Jul 2024 //
BUSINESSWIRE
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
03 Jul 2024 //
BUSINESSWIRE
Viridian Details VRDN-003 Phase 3 Program In Thyroid Eye Disease
11 Jun 2024 //
BUSINESSWIRE
Viridian Reports Inducement Grants Per Nasdaq Rule
06 Jun 2024 //
BUSINESSWIRE
Viridian Announces Inducement Grants Per Nasdaq Rule 5635(c)(4)
06 Jun 2024 //
BUSINESSWIRE
Viridian Announces Upcoming June Investor Conference Participation
31 May 2024 //
BUSINESSWIRE
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
10 May 2024 //
BUSINESSWIRE
Viridian Therapeutics: Recent Progress, Q1 2024 Financials
08 May 2024 //
BUSINESSWIRE
Viridian Announces Nasdaq Listing Rule Inducement Grants
03 May 2024 //
BUSINESSWIRE
Viridian Therapeutics Q1 2024 Results Webcast on May 8
29 Apr 2024 //
BUSINESSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2024 //
BUSINESSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2024 //
BUSINESSWIRE
Viridian to Participate in the Leerink Partners Global Biopharma Conference
05 Mar 2024 //
BUSINESSWIRE
Viridian Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
BUSINESSWIRE
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
16 Feb 2024 //
BUSINESSWIRE
Viridian Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Feb 2024 //
BUSINESSWIRE
Viridian Announces Proposed Underwritten Public Offering of Common Stock
17 Jan 2024 //
BUSINESSWIRE
Viridian Announces Pricing of Public Offering of Shares of Common Stock
17 Jan 2024 //
BUSINESSWIRE
Viridian to Present Key 2024 Priorities at J.P. Morgan Healthcare Conference
08 Jan 2024 //
BUSINESSWIRE
Viridian to Webcast Presentation at the 42nd Annual J.P. Morgan Conference
04 Jan 2024 //
BUSINESSWIRE
Viridian Therapeutics Announces Positive Data in Healthy Volunteer Study
18 Dec 2023 //
BUSINESSWIRE
Viridian to Participate in 6th Annual Evercore ISI HealthCONx Conference
21 Nov 2023 //
BUSINESSWIRE
Viridian Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
BUSINESSWIRE
Viridian Therapeutics to Participate in Jefferies London Healthcare Conference
08 Nov 2023 //
BUSINESSWIRE
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting
03 Nov 2023 //
BUSINESSWIRE
Viridian Therapeutics Appoints New Chief Executive Officer
30 Oct 2023 //
BUSINESSWIRE
Viridian inks $185M financing, hires three Magenta executives as CEO
30 Oct 2023 //
ENDPTS
Viridian Enters Autoinjector Pen Device Customization and Agreement with Ypsomed
26 Oct 2023 //
BUSINESSWIRE
Viridian Announces Presentations at Multiple Medical Meetings in September
07 Sep 2023 //
BUSINESSWIRE
Viridian Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04 Aug 2023 //
BUSINESSWIRE
Viridian Announces Positive Data from Phase 1/2 Trial Evaluating VRDN-001
10 Jul 2023 //
BUSINESSWIRE
Viridian looks to beat Horizon`s Tepezza in thyroid eye disease
10 Jul 2023 //
FIERCE BIOTECH
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06 Jul 2023 //
BUSINESSWIRE
Viridian Announces Presentations at the 2023 Annual Meeting of Endocrine Society
13 Jun 2023 //
BUSINESSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jun 2023 //
BUSINESSWIRE
Viridian Therapeutics Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator
08 May 2023 //
GLOBENEWSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 May 2023 //
GLOBENEWSWIRE
Viridian Therapeutics to Webcast 1Q 2023 FYRÂ & Corporate Update on May 9, 2023
02 May 2023 //
GLOBENEWSWIRE
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting
20 Apr 2023 //
GLOBENEWSWIRE
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
12 Apr 2023 //
GLOBENEWSWIRE
Viridian Reports Fourth Quarter and Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
Viridian Announces Presentations at Meeting of Neuro-Ophthalmology Society
07 Mar 2023 //
GLOBENEWSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2023 //
GLOBENEWSWIRE
Viridian Therapeutics to Webcast 4Q & Full Year 2022 FYR on March 8, 2023
01 Mar 2023 //
GLOBENEWSWIRE
Viridian Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
GLOBENEWSWIRE
Viridian to Participate in SVB Securities Virtual Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Viridian Appoints Scott Myers as President and Chief Executive Officer
06 Feb 2023 //
GLOBENEWSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02 Feb 2023 //
GLOBENEWSWIRE
